We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NitroMed Ties Gene Biomarkers to BiDil Benefit.
- Authors
Davies, Kevin
- Abstract
The article focuses on the genetic factors that affect response to BiDil, the heart failure drug for African-Americans, discussed at the annual meeting of the American College of Cardiology in Atlanta, Georgia in March 2006. NitroMed, maker of BiDil, enrolled 360 of the 1,050 African-American patients who participated in the original African American Heart Failure Trial in a new study called the "Genetic Risk Assessment in Heart Failure (GRAHF)." The frequency of genotypes were determined amongst African American patients in GRAHF compared with white patients. Michael Sabolinski, chief medical officer of NitroMed, insists that every African-American patient with heart failure will show improvement with BiDil.
- Subjects
UNITED States; CLINICAL drug trials; HEART failure treatment; DISEASES in African Americans; HEART disease genetics; NITROMED Inc.
- Publication
Bio-IT World, 2006, Vol 5, Issue 3, p21
- ISSN
1538-5728
- Publication type
Article